News & Views

  • Investment takes Stem Cell Development towards Mass Production
    Maxime Feyeux (left) and Kevin Alessandri (Credit:TreeFrog Therapeutics)

Investment takes Stem Cell Development towards Mass Production

Jun 14 2019 Read 485 Times

A Series A funding round that raised €7.1M ($7.8M), has set Treefrog Therapeutics (Bordeaux) pathway for the transition of its C-Stem™ technology to cGMP standards by 2021, with the development of proprietary and collaborative cell therapy research programs in a wide array of indications (Huntington’s disease, Parkinson’s disease, heart failure, diabetes, NASH…) with the objective of a first-in-man clinical trial in 2024.
The funding round was led by French-German venture capital team XAnge (Siparex Group), joined by private equity fund Galia Gestion as a new investor and historical investors from the earlier seed funding round, Irdi Soridec, Aquiti Gestion and SATT Aquitaine.
In addition to attracting €6.5M ($7.2M) in equity, TreeFrog Therapeutics was granted a further€600k ($670k) non-dilutive funding in March by the Nouvelle-Aquitaine Region, Bpifrance and the French Ministry of Higher Education, Research and Innovation. Over the past four years, the project has already received a total of €3M ($3.3M) from the University of Bordeaux, the French National Centre for Scientific Research (CNRS), the French National Research Agency (ANR) and the Technology Transfer Office for the Nouvelle-Aquitaine region, France (AST Innovations).
The company’s key proprietary technology has shown some promising results for the mass production of stem cells with short lead times. The first batch of 143 million human IPS cells were reportedly amplified in only seven days - without about ten times higher than current industry standards - and genomic integrity proved 100% preserved by the Imagine Institute in Paris.
“This Series A round marks the culmination of a global fundraising effort, which includes seed capital and non-dilutive funds, to the amount of approximately €8M ($9M). We now have the resources to meet our milestones, build our capacities and secure our plan for growth. In addition to the investors who have put their trust in us, we are very grateful to the French Investment Bank Bpifrance, the Nouvelle-Aquitaine Regional Council, the bioproduction school ENSTBB and the UNITEC incubator for their support,” said Maxime Feyeux, president, CSO, TreeFrog Therapeutics.
“I am delighted to complete this funding cycle so quickly. Within the past six months, we have been approached by several big pharma companies to develop novel cell therapy programs. Now, all the lights are green as we move forward with our partners with the aim of a first-in-man clinical trial within three to five years,” said Kevin Alessandri, CEO & CTO, TreeFrog Therapeutics.

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment

Digital Edition

International Labmate November 2019

November 2019

In This Edition Articles - Translating Proteomic MALDi Tissue Typing to Clinical Pathology - Fusion Protein Complexes Analysed by CG-MALS - The Separation and Purification of Glutamine Deri...

View all digital editions



Nov 25 2019 Beijing, China

IFAT India

Dec 05 2019 New Delhi, India

Nepal Lab

Dec 13 2019 Kathmandu, Nepal

SLAS 2020

Jan 25 2020 San Diego, CA, USA

Arab Health

Jan 27 2020 Dubai, UAE

View all events